The effects of neurohormonal antagonism on pathologic left ventricular remodeling in heart failure

Current Cardiology Reports

Volumn 2, Issue 2, 2000, Pages 90-98

  Lombardi, William L ^a   Gilbert, Edward M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

APOPTOSIS; BIOMECHANICS; CONGESTIVE HEART FAILURE; CYTOLOGY; DRUG EFFECT; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; APOPTOSIS; BIOMECHANICS; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; NEUROTRANSMITTER AGENTS; RECEPTORS, ADRENERGIC; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0034150211     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0004-7     Document Type: Article

References (83)

1. Cohn J: Expert Forum on Cardiac Remodeling. Atlanta, GA: April 1998.
2. Kostuk KWJ, Kazamias TM, Gander MP, et al. : Left ventricular size after acute myocardial infarction: serial changes and their prognostic significance. Circulation 1973, 47:1174-1179.
3. White HD, Norris RM, Brown MA, et al. : Left ventricular end-systolic volume as the major determinant of survival after recovery from endomyocardial infarction. Circulation 1987, 76:44-51.
4. Gaudron P, Eilles C, Kugler I, et al. : Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanisms and early predictors. Circulation 1993, 87:755-763.
5. Ertl G, Gaudron P, Neubauer S, et al. : Cardiac dysfunction and development of heart failure. Eur Heart J 1993, 14(suppl A):33-37.
6. Hunter JJ, Grace AA, Chien KR: Molecular and cellular biology of cardiac hypertrophy and failure. In Molecular basis of heart disease: a companion to Braunwald's Heart Disease. Edited by Chien KR. Philadelphia: WB Saunders; 1999:211-250.
7. Xia Z, Dickens M, Raingeaud J, et al. : Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
8. Wang Y, Huang S, Sah VP, et al. : Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 1998, 273:2161-2168.
9. Wang Y, Su B, Sah VP, et al. : Cardiac hypertrophy induced by mitogen-activated protein kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998, 273:5423-5426.
10. Sah VP, Hoshijima M, Chien KR, Brown JH: Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes: dissociation of Ras and Rho pathways. J Biol Chem 1996, 271:311850-31190.
11. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF: Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Am J Pathol 1996, 148:1639-1648.
12. Marijianowski MMH, Teeling PT, Mann J, Becker AE: Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 1995, 25:1263-1272.
13. Anversa P, Ricci R, Olivetti G: Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review. J Am Coll Cardiol 1986, 7:1140-1149.
14. Messerli F: Pathophysiology of left ventricular hypertrophy. In Left Ventricular Hypertrophy and its regression. Edited by Cruickshang J, Messerli F. London: Science Press; 1992.
15. Baig MK, Mahon N, McKenna, et al. : The pathophysiology of advanced heart failure. Am Heart J 1998, 135:S216-S230.
16. Olivetti G, Abbi R, Quaini F, et al. : Apoptosis in the failing human heart. N Engl J Med 1997, 336:1131-1141.
17. MacLellan WR, Schneider MD: Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res 1997, 81:137-144.
18. Teiger E, Dam T-V, Richard L, et al. : Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest 1996, 97:2891-2897.
19. James TN, St. Martin E, Willis PWI, et al. : Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with the absence of the AB node, sinus node, and internodal pathways. Circulation 1996, 93:1424-1438.
20. Hamet P, Moreau P, Dam T-V, et al. : The time window of apoptosis: a new component in the therapeutic strategy for cardiovascular remodeling. J Hypertens 1996, 14(suppl 5):65-70.
21. Katz AM: Cardiomyopathy of overloads: a major determinant of prognosis in congestive heart failure. N Engl J Med. 1990, 322:100-110.
22. Karam R, Healy BP, Wicker P: Coronary reserve is depressed in postmyocardial infarction reactive cardiac hypertrophy. Circulation 1990, 81:238-246.
23. Anversa P, Beghi C, Kikkawa Y, et al. : Myocardial infarction in rats: infarct size, myocyte hypertrophy and capillary growth. Circ Res 1986, 58:26-37.
24. McDonald KM, Yoshiyama M, Francis GS, et al. : Abnormal myocardial bioenergetics in canine asymptomatic left ventricular dysfunction. J Am Coll Cardiol 1994, 23:786-793.
25. Zhang J, McDonald KM: Bioenergetic consequences of left ventricular remodeling. Circulation 1995, 92:1011-1019.
26. Apstein CS, Mueller M, Hood WBJ: Ventricular contracture and compliance changes with global ischemia and reperfusion and their effect on coronary resistance in the rat. Circ Res 1977, 41: 206-217.
27. Fowler MB, Laser JA, Hopkins GL, et al. : Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsensitivity to agonist response. Circulation 1986, 74:1290-1302.
28. Port JD, Gilbert EM, Larrabee P, et al. : Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation 1990, 81:929-938.
29. White M, Yanowitz F, Gilbert EM, et al. : Role of beta adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995, 76:1271-1276.
30. Bristow MR, Ginsburg R, Umans V, et al. : Beta-1 and beta-2 adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta-1 receptor downregulation in heart failure. Circ Res 1986, 59:297-309.
31. Huang LY, Tholanikunnel BG, Vakalopoulou E, et al. : The M(r) 35, 000 beta-adrenergic receptor mRNA-binding protein induced by beta agonists requires both an AUUUA pentamer and U-rich domains for RNA recognition. J Biol Chem 1993, 268:25769-25775.
32. Port JD, Huang LY, Malbon CC: Beta adrenergic agonists that downregulate receptor mRNA upregulate a M(r) 35, 000 protein(s) that selectively binds to beta-adrenergic receptor mRNAs. J Biol Chem 1992, 267:24103-24108.
33. Bristow MR, Herschberger RE, Port JD, et al. : Beta-1 and beta-2 adrenergic receptor-mediated adenylate cyclase stimulation in non-failing and failing human ventricular myocardium. Mol Pharmacol 1989, 35:295-303.
34. Bristow MR, Anderson FL, Port JD, et al. : Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991, 84:1024-1039.
35. Bristow MR, Sandoval AB, Gilbert EM, et al. : Myocardial alpha and beta adrenergic receptors in heart failure: is cardiac-derived norepinephrine the regulatory signal? Eur Heart J 1988, 9:35-40.
36. Vago T, Bevilacqua M, Norbiator G, et al. : Identification of alpha-1 adrenergic receptors on sarcolemma from normal subjects and patients with idiopathic dilated cardiomyopathy: characteristics and linkage to GTP-binding protein. Circ Res 1989, 64:474-481.
37. Starksen NF, Simpson PC, Bishopric N, et al. : Cardiac myocyte hypertrophy is associated with c-myc proto-oncogene expression. Proc Natl Acad Sci USA 1986, 83:8348-8350.
38. Ostman-Smith I: Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy. Clin Sci 1981, 1:265-272.
39. Goodfriend TL, Elliot ME, Catt KJ: Angiotensin receptors and their antagonists. N Engl J Med 1996, 334:1649-1654.
40. Ohyama K, Yamano Y, Chaki SW, et al. : Domains of G-protein coupling in angiotensin II receptor type 1: studies by site-directed mutagenesis. Biochem Biophys Res Commun 1992, 189:677-683.
41. Catt KJ, Sandberg K, Balla T: Angiotensin II receptor and signal transduction mechanisms. In Cellular and Molecular Biology of the Renin-Angiotensin System. Edited by Raizada MK, Phillips MI, Sumners C. Boca Raton, FL: CRC Press; 1993:307-356.
42. Spat A, Enyedi P, Hajnoczky G, et al. : Generation and role of calcium signal in adrenal glomerulosa cells. Exp Physiol 1991, 76:859-885.
43. Bhat GJ, Thekkumkara TJ, Thomas WG, et al. : Angiotensin II stimulates sis-inducing factor-like DNA binding activity: evidence that the AT1A receptor activates transcription factor Stat91 and/or a related protein. J Biol Chem 1994, 264:31443-31449.
44. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993, 73:412-423.
45. Gibbons GH, Dzau VJ: The emerging concept of vascular remodeling. N Engl J Med 1994, 330:1431-1438.
46. Villarreal FJ, Kim NN, Gilanthony D, et al. : Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993, 88:2849-2861.
47. Sadoshima J-I, Izumo S: Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Role of phospholipid-derived second messengers. Circ Res 1993, 73:424-438.
48. Nahmias C, Strosberg AD: The angiotensin AT2 receptor: searching for signal-transduction pathways and physiological function. Trends Pharmacol Sci 1995, 6:223-225.
49. Katz AM: Protein families that mediate Ca2+ signaling in the cardiovascular system. Am J Cardiol 1996, 78(suppl 9A):2-6.
50. Stoll M, Steckelings UM, Paul M, et al. : The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995, 95:651-657.
51. Buisson B, Bottari SP, de Gasparo M, et al. : The angiotensin AT2 receptor modulates inhibition of cell proliferation in coronary endothelial cells. FEBS Lett 1992, 309:161-164.
52. Chiu AT, Roscoe WA, McCall DE, et al. : Angiotensin per trophic responses in rat aortic smooth muscle cells. Receptor 1991, 1:133-140.
53. Steinberg MI, West SA, Palkowitz AD: Non-peptide angiotensin II receptro antagonists. Cardiovasc Drug Rev 1993, 11:312-358.
54. Hall SA, Cigarroa CG, Marcoux L, et al. : Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with betaadrenergic blockade. J Am Coll Cardiol 1995, 25:1154-1161.
55. Lowes BD, Gill EA, Abraham WT, et al. : Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999, 83:1201-1205.
56. Schiller NB, Skioldebrand CG, Schiller EJ, et al. : Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation 1983, 68:210-216.
57. Feiring AJ, Rumberger JA, Reiter SJ, et al. : Determination of left ventricular mass in dogs with rapid-acquisition cardiac computed tomographic scanning. Circulation 1985, 72:1355-1364.
58. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983, 2:755-763.
59. Giles TD, Katz R, Sullivan JM, et al. : Short-and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol 1989, 13:1240-1247.
60. Chalmers JP, West MJ, Cyran J, et al. : Placebo-controlled study of lisinopril in congestive heart failure: a multicenter study. J Cardiovasc Pharmacol 1987, 9(suppl 3):89-97.
61. Cohn JN, Johnson G, Ziesche S, et al. : A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
62. Greenberg B, Quinones MA, Koilpillai C, et al. : Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulatioin 1995, 91:2573-2581.
63. Pfeffer MA, Lamas GA, Vaughan DE, et al. : Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1988, 319:80-86.
64. St. John Sutton M, Pfeffer MA, Moye L, et al. : Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril. Information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997, 96:3294-3299.
65. St. John Sutton M, Pfeffer MA, Plappert T, et al. : Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994, 89:68-75.
66. Bristow MR, Roden RL, Lowes BD, et al. : The role of thirdgeneration beta-blocking agents in chronic heart failure. Clin Cardiol 1998, 21(suppl I):3-13.
67. Gilbert EM, Abraham WT, OLsen S, et al. : Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996, 94:2817-2825.
68. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
69. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 35:2001-2007.
70. Packer M, Bristow MR, Cohn JN, et al. : The effect of carvedilol on morbidity and mortality in patients with chronic congestive heart failure. N Engl J Med 1996, 334:1349-1355.
71. Bristow MR, O'Connel JB, Gilbert EM, et al. : Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 1994, 89:1632-1642.
72. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet 1990, 336:1-6.
73. Lechat P, Pacer M, Chalon S, et al. : Clinical effects of betaadrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998, 98:1184-1191.
74. Bristow MR, Gilbert EM, Abraham WT, et al. : Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996, 94:2807-2816.
75. Eichhorn EJ, Bedotto JB, Malloy CR, et al. : Effect of betaadrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990, 82:473-483.
76. Eichhorn EJ, Hersch CM, Barnett JH, et al. : Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: double-blind, placebo-controlled study. J Am Coll Cardiol 1994, 24:1310-1320.
77. Quaife RA, Christian PE, Gilbert EM, et al. : Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol 1998, 81: 247-250.
78. Doughty RN, Whalley GA, Gamble G, et al. : Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997, 29:1060-1066.
79. Gilbet EM, Munger MA, Renlund DG, et al. : Are the beneficial effects of carvedilol in heart failure sustained long term [abstract]? Eur Heart J 1997, 18(suppl):399(P2264).
80. Di Lenarda A, Sabbadini G, Salvatore L, et al. : Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999, 33:1926-1934.
81. Metra M, Nodari S, D'Aloia A, et al. : Effects of chronic beta-blockade on the haemodynamics and functional capacity of patients with heart failure: a randomized comparison between metoprolol and carvedilol. Eur Heart J 1998, 19(suppl V-VIII):P1720.
82. Kukin ML, Kalman J, Charney RH, et al. : Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99:2645-2651.
83. Sanderson JE, Chan SK, Yip G, et al. : Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999, 34:1522-1528.